An RCT of metformin versus orlistat for the management of obese anovulatory women
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Treatment of obesity-related anovulation poses a significant clinical challenge. Occasionally, the use of antiobesity medications such as orlistat or insulin sensitizing agents such as metformin is sometimes indicated in these patients. This study aimed to compare the effects of metformin and orlistat for improving ovulation in obese anovulatory women. METHODS: This was an open-label RCT. A total of 40 women were randomized to receive either metformin (n = 20) or orlistat (n = 20). BMI as well as the androgen profile and the ovulatory status were assessed at baseline and at four weekly intervals for 3 months. Different anthropometric and endocrine parameters were also assessed as possible predictors of ovulation. RESULTS: There was no significant difference between the two study arms regarding the ovulation rate for metformin and orlistat [40% (n = 8/20) and 25% (n = 5/20), respectively, P = 0.31]. Both arms showed a significant drop in the BMI, testosterone and androstendione concentrations (P < 0.05), but there was no difference between the two arms. Patients who ovulated had significantly lower concentrations of baseline LH, androstendione, dehydroepiandrosterone and free androgen index (P < 0.05). Among these factors, a low baseline LH was found to be the only independent predictor of ovulation (area under curve, 0.85). CONCLUSIONS: Both metformin and orlistat show a similar effect on weight loss, ovulation rates and androgen concentrations. However, the effects on ovulation rates need to be confirmed in larger studies. The presence of a low baseline serum LH was found to be the most important predictor of ovulation. The study was registered at clinicaltrials.gov. NCT00292799.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome
Legro, R. S., Barnhart, H. X., Schlaff, W. D., Carr, B. R., Diamond, M. P., Carson, S. A., Steinkampf, M. P., Coutifaris, C., McGovern, P. G., Cataldo, N. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063971 · Cited by 1,027
Nordmann, A. J., Nordmann, A., Briel, M., Keller, U., Yancy, W. S., Brehm, B. J., & Bucher, H. C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.285 · Cited by 973
Clark, A. M., Thornley, B., Tomlinson, L., Galletley, C., & Norman, R. J. (1998) · Human Reproduction · doi:10.1093/humrep/13.6.1502 · Cited by 789
Metformin in polycystic ovary syndrome: systematic review and meta-analysis
Lord, J. M., Flight, I. H. K., & Norman, R. J. (2003) · BMJ · doi:10.1136/bmj.327.7421.951 · Cited by 786
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Clark, A. M., Ledger, W., Galletly, C., Tomlinson, L., Blaney, F., Wang, X., & Norman, R. J. (1995) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a135772 · Cited by 642
Self-citationMoran, L. J., Noakes, M., Clifton, P. M., Tomlinson, L., & Norman, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020815 · Cited by 530
Lee, A., & Morley, J. E. (1998) · Obesity Research · doi:10.1002/j.1550-8528.1998.tb00314.x · Cited by 320
Lukanova, A., Lundin, E., Zeleniuch-Jacquotte, A., Muti, P., Mure, A., Rinaldi, S., Dossus, L., Micheli, A., Arslan, A., Lenner, P., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500161 · Cited by 315
Metformin for the treatment of the polycystic ovary syndrome
Nestler, J. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmct0707092 · Cited by 313
Mannucci, E., Ognibene, A., Cremasco, F., Bardini, G., Mencucci, A., Pierazzuoli, E., Ciani, S., Messeri, G., & Rotella, C. M. (2001) · Diabetes Care · doi:10.2337/diacare.24.3.489 · Cited by 300
Huber-Buchholz, M.-M. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.4.1470 · Cited by 269
Role of Diet in the Treatment of Polycystic Ovary Syndrome
Douglas, C. C., Gower, B. A., Darnell, B. E., Ovalle, F., Oster, R. A., & Azziz, R. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.08.045 · Cited by 170
A systematic review of the clinical effectiveness of orlistat used for the management of obesity
O'Meara, S., Riemsma, R., Shirran, L., Mather, L., & Ter Riet, G. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00125.x · Cited by 103
Loverro, G., Lorusso, F., De Pergola, G., Nicolardi, V., Mei, L., & Selvaggi, L. (2002) · Gynecological Endocrinology · doi:10.1080/713603060 · Cited by 27
Cited by
Garvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
The adverse effects of obesity on conception and implantation
Brewer, C. J., & Balen, A. H. (2010) · Reproduction · doi:10.1530/rep-09-0568 · Cited by 491
Cardiometabolic Aspects of the Polycystic Ovary Syndrome
Randeva, H. S., Tan, B. K., Weickert, M. O., Lois, K., Nestler, J. E., Sattar, N., & Lehnert, H. (2012) · Endocrine Reviews · doi:10.1210/er.2012-1003 · Cited by 322
Panidis, D., Tziomalos, K., Papadakis, E., Chatzis, P., Kandaraki, E. A., Tsourdi, E. A., & Katsikis, I. (2014) · Clinical Endocrinology · doi:10.1111/cen.12305 · Cited by 43
Moini, A., Kanani, M., Kashani, L., Hosseini, R., & Hosseini, L. (2015) · Endocrine · doi:10.1007/s12020-014-0426-4 · Cited by 37
“In the current study, the intervention group showed a significant reduction in testosterone levels which was consistent with other reports for PCOS patients [17, 18].”
Result
Metadata
- Authors
- Metwally, M., Amer, S., Li, T. C., & Ledger, W. L.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-12-26
- Volume
- 24
- Issue
- 4
- Pages
- 966-975
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2119905410
- Cited by
- 47
- References
- 15
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.